Page last updated: 2024-11-02

pioglitazone and Glomerulonephritis, IGA

pioglitazone has been researched along with Glomerulonephritis, IGA in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Glomerulonephritis, IGA: A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zou, JN1
Xiao, J1
Hu, SS1
Fu, CS1
Zhang, XL1
Zhang, ZX1
Lu, YJ1
Chen, WJ1
Ye, ZB1

Other Studies

1 other study available for pioglitazone and Glomerulonephritis, IGA

ArticleYear
Toll-like Receptor 4 Signaling Pathway in the Protective Effect of Pioglitazone on Experimental Immunoglobulin A Nephropathy.
    Chinese medical journal, 2017, Apr-20, Volume: 130, Issue:8

    Topics: Animals; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Glome

2017
chemdatabank.com